title: Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study.
abstract: OBJECTIVE
  The aim of this study was to compare clinicopathologic characteristics, surgery outcomes and survival outcomes of patients with stage III and IV mucinous epithelial ovarian cancer (mEOC) and serous epithelial ovarian carcinoma (sEOC).
  
  
  METHODS
  Patients who had surgery for advanced stage (III or IV) mEOC were evaluated retrospectively and defined as the study group. Women with sEOC who were matched for age and stage of disease were randomly chosen from the database and defined as the control group. The baseline disease characteristics of patients and platinum-based chemotherapy efficacy (response rate, progression-free survival and overall survival [OS]) were compared.
  
  
  RESULTS
  A total of 138 women were included in the study: 50 women in the mEOC group and 88 in the sEOC group. Patients in the mEOC group had significantly less grade 3 tumors and CA-125 levels and higher rate of para-aortic and pelvic lymph node metastasis. Patients in the mEOC group had significantly less platinum sensitive disease (57.9% vs. 70.8%; p=0.03) and had significantly poorer OS outcome when compared to the sEOC group (p=0.001). The risk of death for mEOC patients was significantly higher than for sEOC patients (hazard ratio, 2.14; 95% confidence interval, 1.34 to 3.42).
  
  
  CONCLUSIONS
  Advanced stage mEOC patients have more platinum resistance disease and poorer survival outcome when compared to advanced stage sEOC. Therefore, novel chemotherapy strategies are warranted to improve survival outcome in patients with mEOC.
authors: Department of Gynecologic Oncology, Etlik Zübeyde Hanım Women's Health Teaching and Research Hospital, Ankara, Turkey.
authors: Emine
authors: E
authors: Karabuk
authors: M Faruk
authors: MF
authors: Kose
authors: Deniz
authors: D
authors: Hizli
authors: Salih
authors: S
authors: Taşkin
authors: Burak
authors: B
authors: Karadağ
authors: Taner
authors: T
authors: Turan
authors: Nurettin
authors: N
authors: Boran
authors: Ahmet
authors: A
authors: Ozfuttu
authors: U Fırat
authors: UF
authors: Ortaç
keywords: Chemosensitivity; Mucinous epithelial ovarian cancer; Serous epithelial ovarian cancer; Survival
references: J Clin Oncol. 2007 Aug 1;25(22):3302-6
references: 17664478
references: Am J Obstet Gynecol. 2011 Nov;205(5):480.e1-8
references: 21861962
references: Int J Gynecol Cancer. 2010 Aug;20(6):945-52
references: 20683400
references: J Clin Oncol. 2004 Mar 15;22(6):1040-4
references: 15020606
references: Gynecol Oncol. 2008 Jun;109(3):370-6
references: 18395777
references: Natl Cancer Inst Monogr. 1975 Oct;42:101-4
references: 1234624
references: Cancer. 2004 Mar 15;100(6):1152-61
references: 15022281
references: Gynecol Oncol. 2009 Jun;113(3):331-4
references: 19275957
references: Oncol Rep. 1998 Jan-Feb;5(1):99-101
references: 9458301
references: BMC Cancer. 2008 Sep 01;8:252
references: 18761742
references: Gynecol Oncol. 2005 May;97(2):436-41
references: 15863142
references: J Clin Oncol. 2002 Mar 1;20(5):1248-59
references: 11870167
references: J Clin Oncol. 1991 Jul;9(7):1138-50
references: 1904477
references: Int J Gynecol Cancer. 2010 Oct;20(7):1290-8
references: 21151709
references: Ann Acad Med Singap. 1998 Sep;27(5):650-6
references: 9919334
references: N Engl J Med. 1996 Jan 4;334(1):1-6
references: 7494563
references: Cancer. 2010 Mar 15;116(6):1462-8
references: 20108307
references: Cancer. 2011 Feb 1;117(3):554-62
references: 20862744
references: Eur J Surg Oncol. 2009 Oct;35(10):1105-8
references: 19443175
references: Ann Oncol. 2010 Dec;21(12):2377-2381
references: 20494964
references: Cancer Lett. 2003 Mar 31;192(2):227-35
references: 12668287
references: Cancer. 2009 Apr 1;115(7):1395-403
references: 19195045